Empagliflozin Treatment in Kidney Transplant Recipients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 264 participants.

Also called NCT06013865

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 264 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06013865
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06013865. Allocation not applicable; no masking; primary purpose treatment. Start 2024-04-05 (actual); primary completion 2030-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Empagliflozin Treatment in Kidney Transplant Recipients
Acronym
SEKTR
Condition
Kidney Transplant
Intervention (Drug)
Empagliflozin
Lead sponsor
VA Office of Research and Development (class: US federal agency)
Collaborator
Iowa City VA Health Care System (class: US federal agency)
Collaborator
VA Pittsburgh Healthcare System (class: US federal agency)
Collaborator
VA Tennessee Valley Health Care System (class: US federal agency)
Collaborator
VA Hines Health Care (class: not stated)

Record details

Record id
cardio:ct-nct06013865
Content hash
ab26ae8ac52d4933ab143d9723804ce6c307f6e4ab10dac42f56c55e83eced7d